Masimo Co. (NASDAQ:MASI) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC reduced its holdings in shares of Masimo Co. (NASDAQ:MASI) by 4.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,155 shares of the medical equipment provider’s stock after selling 185 shares during the period. Private Advisor Group LLC’s holdings in Masimo were worth $554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. NBC Securities Inc. grew its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 73 shares during the last quarter. GAMMA Investing LLC grew its position in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares in the last quarter. HHM Wealth Advisors LLC raised its holdings in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 573 shares during the period. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MASI. Piper Sandler reissued an “overweight” rating on shares of Masimo in a research report on Friday, October 18th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Finally, BTIG Research raised their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $145.33.

Masimo Price Performance

Shares of MASI opened at $144.22 on Monday. The business’s 50-day moving average is $129.44 and its two-hundred day moving average is $125.14. The company has a market capitalization of $7.67 billion, a P/E ratio of 98.11 and a beta of 0.97. Masimo Co. has a fifty-two week low of $75.36 and a fifty-two week high of $153.93. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm had revenue of $496.30 million for the quarter, compared to analyst estimates of $493.92 million. During the same period last year, the company earned $0.62 earnings per share. Masimo’s revenue for the quarter was up 9.0% compared to the same quarter last year. Research analysts predict that Masimo Co. will post 3.88 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.